Xiidra® savings & support

We’re here to help. See what resources are available for
dry eye disease patients.

sticky line
Ken Jeong
sticky line

Xiidra® savings & support

We’re here to help.
See what resources are available for dry eye disease patients.

megaphone

Effective July, 1 2022:

SIGNIFICANTLY broader coverage for your Medicare patients

Xiidra is now covered for nearly 3 out of 4* Medicare Part D patients!

Xiidra is now on the lowest branded co-pay tier and requires no prior authorization on:

  • SilverScript Medicare
  • Express Scripts® Medicare EGWP
  • Aetna® Medicare
  • WellCare™ Classic PDP
  • Cigna® Medicare

Choose Xiidra as your first-choice prescription DED treatment.

Prescribe with confidence for a 90-day Rx.

*Approximately 70% as of 7/1/22.
Coverage information from data on file.
DRF Fingertip Formulary® Novartis Pharmaceutical Corp; July 2022

megaphone

*Approximately 70% as of 7/1/22. Coverage information from data on file. DRF Fingertip Formulary® Novartis Pharmaceutical Corp; July 2022

For your patients with commercial insurance

megaphone

Xiidra has comparable or better coverage to Restasis for 88% of commercially insured patients2

Based on Commercial Formulary Access in National and Regional Accounts on January 18, 2022.


Confirm formulary coverage for your patients


Xiidra Savings Program

Help your commercially insured patients reduce their medication cost

copay card $0 Xiidra savings card

On average, patients paid $45 for 90 days (or $15 per month) for OTC artificial tears.3‡

Based on average dollars per month spent on over-the-counter dry eye products by patients active in both the IQVIA LRx and OTC databases (n=2,258,782). Eligible patients must have at least one record of prescription activity (from any market) in the LRx database prior to the look-back period and at least one record of OTC activity. Calculation was completed by IQVIA based on a study period from November 2018 to October 2019.

*Limitations apply. Valid for patients with private (commercial) insurance only. The Xiidra Co-pay card Program includes the Co-pay Card and rebate. Eligible, commercially insured patients using the Co-pay Card pay $0 for their first prescription of Xiidra. $0 first fill available for prescriptions up to 90 days. After the first fill, eligible, commercially insured patients may pay as little as $0 for prescriptions of Xiidra, subject to a maximum monthly savings of $250 for each 30-day prescription and $750 for each 90-day prescription. Patient is responsible for any costs once monthly savings limit is reached. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, or (iii) where the patient’s insurance plan reimburses for the entire cost of the drug. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party, rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

FOOTNOTES

Limitations apply. Valid for patients with private (commercial) insurance only. The Xiidra Co-pay card Program includes the Co-pay Card and rebate. Eligible, commercially-insured patients using the Co-pay Card pay $0 for their first prescription of Xiidra. $0 first fill available for prescriptions up to 90 days. After the irst fill, eligible, commercially-insured patients may pay as early as $0 for prescriptions of Xiidra, subject to a maximum monthly savings of $250 for each 30-day prescription and $750 for each 90-day prescription. Patient is responsible for any costs once monthly savings limit is reached. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, or (iii) where the patient’s insurance plan reimburses for the entire cost of the drug. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party, rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.


Based on average dollars per month spent on over-the-counter dry eye products by patients active in both the IQVIA LRx and OTC databases (n=2,258,782). Eligible patients must have at least one record of prescription activity (from any market) in the LRx database prior to the look-back period and at least one record of OTC activity. Calculation was completed by IQVIA based on a study period from November 2018 to October 2019.

For patients experiencing
financial hardship, and have
limited or no prescription
coverage, contact
800-277-2254 or visit www.PAP.Novartis.com.

Patients who are eligible may receive their medication for free.

For more on helping patients start and stay on Xiidra, including questions around cost and affordability such as Xiidra’s $0 Co-Pay Program for commercially eligible patients or the Insider Support Program, please call the Xiidra Access Program at 1-877-4Xiidra (1-877-494-4372).

Xiidra Prior Authorization Checklist

megaphone

Ensure seamless access assistance for appropriate patients with this easy-to-use Prior Authorization Checklist

eye icon

Xiidra patient
resource

Help your patients learn more about Xiidra and the relief it can offer for their dry eye symptoms.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.